Eli Lilly reported second-quarter adjusted earnings per share of $8.38, compared to $6.31 in the same period last year, with revenue reaching $22.97 billion, exceeding the $20.59 billion forecast by analysts.

The company raised its full-year revenue outlook to a range of $85 billion to $87 billion, up from the previous forecast of $82 billion to $85 billion. Eli Lilly also expects full-year adjusted earnings per share to be between $35.50 and $36.50, narrowing from the earlier range of $35.50 to $37.

In pre-market trading, Eli Lilly shares rose approximately 4%.

Risk Warning and Disclaimer

Market conditions carry risks, and investment requires caution. This article does not constitute personal investment advice and does not consider the specific investment objectives, financial situations, or needs of individual users. Readers should evaluate whether any opinions, views, or conclusions presented herein align with their particular circumstances. Investment decisions based on this content are at your own risk.